Altasciences Completes Acquisition of Preclinical Testing Business and Hires Key Staff
LAVAL, Quebec--(BUSINESS WIRE)--Oct 1, 2018--Altasciences today announced the completion of the acquisition of a preclinical testing business in Everett, Washington. This transaction will support Altasciences’ goal of being a mid-sized CRO that will provide talent and scale to support the preclinical and clinical markets while creating a new outsourcing paradigm for its clients.
“Our vision is to become the first CRO to build a service offering allowing for multiple points of entry that flows seamlessly from lead candidate selection to proof of concept. We now have more than 1,300 staff members in two countries working together to bring our customers the best possible services,” said Steve Mason, Executive Vice President, Site Operations, at Altasciences.
Altasciences also confirmed today three key additions to the Seattle team who already boast significant expertise in preclinical testing. Michael Broadhurst has joined Altasciences as General Manager, Preclinical Safety Testing Operations; Francis Douville has joined as Vice President, Operations; and Julie Forget has joined as Director, Toxicology, and will oversee the Study Director group.
“We specifically hand-picked experienced individuals with whom we worked alongside for many years, back when Charles River in Montreal was known as CTBR. It was essential that we hire people that share our culture and values, and particularly our focus on delivering expert guidance with exceptional customer service. In addition, all three hires understand the importance of integrating our services to provide a coordinated outsourcing experience,” explained Chris Perkin, CEO at Altasciences.
These individuals bring many decades of relevant experience and have been specifically selected to add to Altasciences’ toxicology expertise as well as facilitate integration into the Altasciences vision of a full service early drug development CRO. Both the new hires and existing management will play an integral role as Altasciences prepares to further build and integrate large and small molecule safety testing services.
Altasciences is a contract research organization with a unique focus on supporting drug development from lead candidate selection to proof of concept. Altasciences encompasses Algorithme Pharma in Montreal, QC, Vince & Associates Clinical Research in Overland Park, KS, Algorithme Pharma USA in Fargo, ND, and Altasciences Preclinical Services in Seattle, WA. With over 25 years of industry experience, Altasciences provides preclinical and clinical solutions to an international customer base of biopharmaceutical companies. Altasciences’ full-service solutions offering in this critical stage of drug development includes preclinical safety testing, clinical pharmacology services, medical writing, biostatistics, data management, bioanalysis and overall program management.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005554/en/
Julie-Ann Cabana, 913 304-4505
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
Copyright Business Wire 2018.
PUB: 10/01/2018 08:57 AM/DISC: 10/01/2018 08:57 AM